Department of Clinical Sciences, Ophthalmology, Umeå University, Umeå, Sweden.
Wallenberg Center for Molecular Medicine, Umeå University, Umeå, Sweden.
Invest Ophthalmol Vis Sci. 2020 Oct 1;61(12):17. doi: 10.1167/iovs.61.12.17.
To investigate if decrease of IOP affects the volumetric blood flow rate in the ophthalmic artery (OA) in patients with previously untreated ocular hypertension.
Subjects with untreated ocular hypertension (n = 30; mean age 67 ± 8 years; 14 females) underwent ophthalmologic examination and a 3-Tesla magnetic resonance imaging investigation. The magnetic resonance imaging included three-dimensional high-resolution phase-contrast magnetic resonance imaging to measure the OA blood flow rate. The subjects received latanoprost once daily in the eye with higher pressure, the untreated eye served as control. The same measurements were repeated approximately 1 week later.
The mean OA blood flow rate before and after treatment was 12.4 ± 4.4 and 12.4 ± 4.6 mL/min in the treated eye (mean ± SD; P = 0.92) and 13.5 ± 5.2 and 13.4 ± 4.1 mL/min in the control eye (P = 0.92). There was no significant difference between the treated and control eye regarding blood flow rate before (P = 0.13) or after treatment (P = 0.18), or change in blood flow rate after treatment (0.1 ± 3.1 vs. -0.1 ± 4.0 mL/min, P = 0.84). Latanoprost decreased the IOP by 7.2 ± 3.1 mm Hg in the treated eye (P < 0.01).
The results indicate that a significant lowering of IOP does not affect the blood flow rate of the OA in ocular hypertension subjects. The ability to maintain blood supply to the eye independent of the IOP could be a protective mechanism in preserving vision in subjects with ocular hypertension.
探讨未经治疗的高眼压患者眼压降低是否会影响眼动脉(OA)的容积血流速率。
未经治疗的高眼压患者(n=30;平均年龄 67±8 岁;女性 14 名)接受眼科检查和 3T 磁共振成像检查。磁共振成像包括三维高分辨率相位对比磁共振成像,以测量 OA 血流速率。在眼压较高的眼滴用拉坦前列素,未治疗的眼作为对照。大约 1 周后重复相同的测量。
治疗前和治疗后 OA 的平均血流速率分别为治疗眼 12.4±4.4 和 12.4±4.6mL/min(均值±标准差;P=0.92),和对照眼 13.5±5.2 和 13.4±4.1mL/min(P=0.92)。治疗眼和对照眼之间在血流速率方面,治疗前(P=0.13)和治疗后(P=0.18),或治疗后血流速率的变化(0.1±3.1 与-0.1±4.0mL/min,P=0.84)均无显著差异。拉坦前列素使治疗眼的眼压降低了 7.2±3.1mmHg(P<0.01)。
结果表明,眼压的显著降低不会影响高眼压患者 OA 的血流速率。这种能够独立于眼压维持眼睛供血的能力可能是保护高眼压患者视力的一种保护机制。